Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Denali Therapeutics Inc.
With
Biogen
Age
30–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years
For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years
Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant.
Have a clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria.
You may not be if
Have a history of any clinically significant neurological disorder other than PD, including, but not limited to, stroke and dementia, in the opinion of the investigator, within 5 years of the screening visit.
Have clinical evidence of atypical parkinsonism (eg, multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.
Have previously participated or are currently participating in the BIIB122 LUMA study (Study 283PD201).
Have previously participated or are currently participating in a gene therapy study for PD.
Have a history of brain surgical intervention for PD (eg, deep-brain stimulation, pallidotomy).
Have any physical condition that may confound the motor assessment (MDS-UPDRS) over time (eg, severe arthritis, severe dyskinesias, traumatic injuries with permanent physical disability).
Abnormal vitals including Blood Pressure, Heart Rate, or Body Temperature
Have abnormal PFT results at screening
Clareo Health | Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
